Medigus’ First Multi-center Clinical Study for MUSE™ Approved by CFDA

Medigus of Israel has received CFDA’s approval of the first multi-center clinical study for its MUSE™ system, an FDA cleared and CE marked endoscopic device to perform transoral fundoplication for the treatment of gastroesophageal reflux disease (GERD), in China. Shanghai Golden-Grand Medical Instruments, a Sinopharm’s unit that is specialized in the distribution of medical devices in the gastroenterology field and Medigus' exclusive distributor of MUSE TM  in China, will launch the trial. More details.... Stock Symbols (NASDAQ:  MDGS ) (TASE: MDGS) Share this with colleagues: // //